Zelsuvmi kit is a prescription medicine containing Berdazimer, marketed by Lnhc, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store ZELSUVMI in a refrigerator between 2°C and 8°C (36°F and 46°F) until…
Key facts
- Active ingredient (INN)
- Berdazimer
- Brand
- Zelsuvmi
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Lnhc
- Manufacturer
- Lnhc
- Origin register
- US FDA, United States
- Storage
- Store ZELSUVMI in a refrigerator between 2°C and 8°C (36°F and 46°F) until dispensed to the patient. Do not freeze. Discard 60 days after removal from refrigeration. After Dispensing: Store ZELSUVMI at room temperature, between 20°C to 25°C (68°F and 77°F) in a dry location.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 April 2025
- Identifiers
- RxCUI 2710438, 2710443DailyMed set ID 76b17622-bdb9-41ea-b962-c2acc0df71f7NDC 83787-103Application NDA217424
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 kit * 1 tube in 1 carton / 17 g in 1 tube * 1 tube in 1 carton / 14 g in 1 tube | 83787-103-31 | Lnhc | 4 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 January 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Berdazimer is a prescription medicine indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. It is available as kits. MedsAcross supplies Berdazimer for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BerdazimerFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZELSUVMI prescribing information (LNHC) · U.S. National Library of Medicine, DailyMed
Need Zelsuvmi kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.